Australia's MD Solutions Questions TGA Handling Of Oncura Product
This article was originally published in PharmAsia News
Executive Summary
Australian companies MD Solutions and Oncura, a unit of GE Healthcare of the United States, are at odds over the Therapeutic Goods Administration's handling of competing products
|
Australian companies MD Solutions and Oncura, a unit of GE Healthcare of the United States, are at odds over the Therapeutic Goods Administration's handling of competing products. MD Solutions has raised to the TGA the issue of the lack of review of low-dose rate brachytherapy, which involves implanting radioactive seeds to treat prostate cancer. MD Solutions sells a competing treatment, VariStrand, which successfully completed the TGA's approval process. But MD Solutions questions why Oncura's Rapid Strand Rx also is listed on the Australian Register of Therapeutic Goods and on the Medicare list of approved prostheses when it did not have to undergo the same review process. (Click here for more) "Cancer Therapy Kits Spark Debate" - The Australian (10/9/10) |